However these trials use ETAR-specific antagonists16 without addressing the contribution of ETBR. The role of ETBR in metastasis across different cancer subtypes is poorly understood, and the lack of treatment benefit with ETAR antagonists in clinical trials points to the need to shift the focus to ETBR. We have shown that epigenetic silencing of EDNRB, the gene for ETBR, correlates with neck metastasis in oral SCC patients1. The gene discussed is EDNRB; the disease is cancer.